The Manufacturers Life Insurance Company Reduces Stock Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

The Manufacturers Life Insurance Company lowered its position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 54.5% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 60,665 shares of the company’s stock after selling 72,548 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Taysha Gene Therapies were worth $122,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the business. Creative Planning purchased a new stake in Taysha Gene Therapies in the 3rd quarter valued at about $28,000. Principal Financial Group Inc. acquired a new position in Taysha Gene Therapies in the 2nd quarter valued at about $48,000. China Universal Asset Management Co. Ltd. increased its stake in Taysha Gene Therapies by 79.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 39,417 shares of the company’s stock worth $79,000 after purchasing an additional 17,446 shares during the period. Intech Investment Management LLC acquired a new stake in shares of Taysha Gene Therapies during the third quarter worth about $85,000. Finally, Scientech Research LLC purchased a new position in shares of Taysha Gene Therapies in the second quarter valued at approximately $97,000. 77.70% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on TSHA shares. Needham & Company LLC reaffirmed a “buy” rating and set a $6.00 target price on shares of Taysha Gene Therapies in a research note on Tuesday, November 12th. Chardan Capital restated a “buy” rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a research note on Thursday, November 14th. Cantor Fitzgerald reiterated an “overweight” rating and set a $7.00 price target on shares of Taysha Gene Therapies in a research note on Tuesday, November 12th. JMP Securities reiterated a “market outperform” rating and issued a $5.00 price target on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Finally, Canaccord Genuity Group lifted their price objective on shares of Taysha Gene Therapies from $6.00 to $8.00 and gave the company a “buy” rating in a research report on Friday, November 15th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $6.63.

Taysha Gene Therapies Stock Performance

Shares of TSHA opened at $2.01 on Tuesday. The company has a 50-day moving average of $2.15 and a two-hundred day moving average of $2.34. Taysha Gene Therapies, Inc. has a 12-month low of $1.19 and a 12-month high of $4.32. The stock has a market cap of $411.93 million, a P/E ratio of 3.19 and a beta of 0.79. The company has a current ratio of 5.51, a quick ratio of 5.51 and a debt-to-equity ratio of 0.48.

Taysha Gene Therapies Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.